CASR and neoplasm: Finally, a recent study has shown that cinacalcet, an allosteric activator of the CaSR approved for clinical use (Nemeth et al., 1998), inhibits neuroblastoma tumor growth in vitro and in vivo (Rodríguez-Hernández et al., 2016).